Stockreport

Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? [Yahoo! Finance]

Immunome, Inc.  (IMNM) 
PDF progression versus placebo and plans to seek FDA approval in the second quarter of 2026. This outcome positions Varegacestat as a potentially important therapy candida [Read more]